**7. Outcomes and unanswered questions**

Whereas the postulated effect of rituximab on antibody-production is indirect, bortezomib (Velcade®, Takeda Oncology) acts directly at the level of the antibody-producing plasma cell. Bortezomib is a proteasomal inhibitor that depletes circulating plasma cells by inducing apoptosis [83–85]. The first reported use bortezomib in transplant recipients was in a small series where graft salvage was attempted in the cases of AMR refractory to therapies including TPE, IVIG, and rituximab [86]. Following bortezomib therapy, circulating DSA strength has been reported to decrease substantially [87], though interestingly, class I and class II DSAs may be not be reduced with equal efficacy [88]. Bortezomib, like rituximab, has been used in combination with TPE, with and without steroids and rituximab [89–92] and is thoroughly

384 Organ Donation and Transplantation - Current Status and Future Challenges

The realization that the tissue injury associated with AMR was, at least in part, mediated by the complement cascade led to the hypothesis that complement inhibition may afford tissue-level protection while TPE or other antibody removing techniques were implemented. The first reported use of the terminal complement inhibitor eculizumab (Soliris®, Alexion Pharmaceuticals) was in a patient with severe accelerated oliguric AMR who was deemed an inappropriate candidate for a rescue splenectomy [93]. With TPE, IVIG, rituximab, and eculizumab, recovery of renal function was achieved. Several reports describe the use of eculizumab as a salvage therapy, either in lieu of or in combination with splenectomy [94–96], but reports of successful salvage are not universal [97]. Eculizumab's mechanism of action of action led to studies of its pre-emptive use in incompatible kidney recipients at high risk for AMR, and while eculizumab may decrease the incidence of AMR [98], it does

Additional complement inhibitors have since become available and are being evaluated for their relative efficacy in AMR. C1-esterase inhibitor (C1-INH) is an endogenous protein that is a more proximal inhibitor of the complement cascade and is commercially available as a purified plasma preparation (Berinert®, CSL Behring, and Cinryze®, Shire). A recently reported double-blinded randomized controlled trial of C1-INH as an add-on to standard TPE therapy for AMR suggested a benefit in terms of improved long term renal allograft function in those who received C1-INH [100]. Like eculizumab, C1-INH may have promise in the prevention of AMR in high-risk patients [101], or as a graft protective agent in the setting of severe or treat-

IL-6 is a pro-inflammatory cytokine with properties that activate numerous cell lines including B-T- and plasma cells. Tocilizumab (Actemra®, Genentech)is a humanized monoclonal antibody which blocks IL-6 signal transduction by binding and inhibiting the IL-6 receptor [103]. In animal models, IL-6/IL-6R signaling has been found to promote renal injury [104] and may be associated with the injury of acute rejection [105]. In human studies, it may affect a decrease in HLA antibody production [106]. A recent trial of tocilizumab in patients with refractory chronic AMR reported improved long-term graft survival rates in those who

reviewed elsewhere [85].

not prevent it [99].

ment refractory AMR [102].

received tocilizumab [107].

**6.7. IL-6 inhibition**

**6.6. Complement inhibition**

Generally reported estimates of the incidence of AMR are around 7% for all recipients [108], and may be as high as 50% among recipients of HLA-incompatible grafts [109, 110]. Despite improved abilities to diagnose and treat AMR, it remains an important cause of premature graft loss [111, 112]. Clinically silent AMR identified on biopsy in the setting of normal renal function, if left untreated, is associated with a two-fold increased risk of graft loss [109, 113]. If the AMR is clinically apparent and associated with graft dysfunction, the risk of graft loss can increase to six-fold [109]. Even when recognized and treated promptly, AMR portends recurrent AMR, and ultimately, chronic AMR and transplant glomerulopathy [114, 115].

The pathophysiology of AMR and the molecular mechanisms of antibody-mediated injury have never been better understood, however the fact that such heterogeneity is observed clinically from case to case suggests that much remains yet to be clarified. The spectrum of AMR severity, acuity, and treatability is broad and not easily predictable even when clinical parameters appear relatively constant. While some lines of evidence suggest that any DSA [116, 117] even historical DSA not present at transplant [111], has the potential to be harmful, others have reported clinically silent DSA that, although detectable, has no apparent impact the incidence of rejection or on long-term outcomes [118]. Whether sensitization alone, not just DSA, is an independent risk factor for AMR, is unclear [115]. Whether this variability lies in the DSA specificity, in differential expression of the target HLA molecules on the allograft, or on other factors, remains to be determined. Multiple lines of evidence suggest that complement activating, C1qbinding DSA are associated with greater risks for rejection and for worse outcomes [119–122], compared to non-C1q binding DSAs. The ability to identify and test for the more virulent DSAs may prove to be of benefit in terms of surveillance and directing treatment. There is evidence that class II DSA is associated with worse long-term outcomes [123–125], and poorer responses to treatments [126] compared to class I DSAs. What underlies this difference, remains uncertain. Whether, and how, antigens vary in terms of their immunogenicity and risks for inciting AMR, remains to be determined. Whether any of the available therapies is optimally suited for different DSA patterns or specificities, or AMR phenotypes, also remains to be determined.

Perhaps the most effective means of minimizing the risks of AMR may be in maximizing efforts to prevent it. Experience with HLA-incompatible transplant recipients have demonstrated, both in single-center and multi-center series, that long-term outcomes are inversely correlated with the starting crossmatch strength [19, 20]. Thus careful attention paid to donor selection, and making any effort possible to minimize incompatibility, can pay great dividends in the long-term post-transplant [115]. And while prevention will not always be feasible, the ability to more readily and accurately detect AMR will enable more rapid treatments and improve the chances of their success. Just as new agents are being developed to remove antibody [127], and interrupt the pathways that impart antibody-mediated injury, so too are innovative, increasingly specific, and less invasive procedures for the diagnosis of AMR. The ability to identify AMR, and perhaps even characterize AMR phenotypes based on gene expression profiles in biopsy tissue [128, 129] should allow a clearer determination of AMR severity and ultimately help guide therapy. The identification of serum and/or urinary biomarkers [130–133] should enable better surveillance, earlier diagnosis of AMR, and prompt treatment to prevent irreversible tissue injury. Ultimately, optimizing the diagnosis and treatment of AMR will lead to greater graft longevity and thus, better utilization of this vastly limited resource.

[10] Kissmeyer-Nielsen F et al. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet. 1966;**2**(7465):662-665 [11] Williams GM et al. "Hyperacute" renal-homograft rejection in man. The New England

Diagnosis, Treatment, and Outcomes of Antibody-Mediated Rejection in Kidney Transplantation

http://dx.doi.org/10.5772/intechopen.75770

387

[12] Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplanta-

[13] Tatapudi VS, Montgomery RA. Pharmacologic complement inhibition in clinical trans-

[14] Hariharan S et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. The New England Journal of Medicine. 2000;**342**(9):605-612

[15] Stegall MD, Chedid MF, Cornell LD. The role of complement in antibody-mediated rejection in kidney transplantation. Nature Reviews Nephrology. 2012;**8**(11):670-678 [16] Meier-Kriesche HU et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. American Journal of

[17] Gaston RS et al. Evidence for antibody-mediated injury as a major determinant of late

[18] Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: A critical reappraisal. American Journal of Transplantation. 2011;**11**(3):450-462

[19] Montgomery RA et al. Desensitization in HLA-incompatible kidney recipients and sur-

[20] Orandi BJ et al. Survival benefit with kidney transplants from HLA-incompatible live

[21] Vo AA et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. The New England Journal of Medicine. 2008;**359**(3):242-251 [22] Burns JM et al. Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation. American Journal of Transplantation. 2008;**8**(12):2684-2694

[23] Racusen LC et al. Antibody-mediated rejection criteria – an addition to the Banff 97 classification of renal allograft rejection. American Journal of Transplantation.

[24] Loupy A et al. The Banff 2015 kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. American Journal of

[25] Cecka JM. Calculated PRA (CPRA): The new measure of sensitization for transplant can-

[26] Paramesh AS et al. OPO strategies to prevent unintended use of kidneys exported for high PRA (>98% cPRA) recipients. American Journal of Transplantation. 2017;**17**(8):2139-2143

didates. American Journal of Transplantation. 2010;**10**(1):26-29

tion. The New England Journal of Medicine. 1969;**280**(14):735-739

plantation. Current Transplantation Reports. 2017;**4**(2):91-100

kidney allograft failure. Transplantation. 2010;**90**(1):68-74

vival. The New England Journal of Medicine. 2011;**365**(4):318-326

donors. The New England Journal of Medicine. 2016;**374**(10):940-950

Journal of Medicine. 1968;**279**(12):611-618

Transplantation. 2004;**4**(3):378-383

2003;**3**(6):708-714

Transplantation. 2017;**17**(1):28-41
